Searched for: person:wue12
in-biosketch:true
Development of eruptive keratoacanthoma-like squamous atypia after biologic therapy [Case Report]
Li, Stephen; Wu, Ellen; Arzuaga, Angelica; Lewitt, Michael; Brieva, Joaquin; Amin, Ahmad
PMCID:12256292
PMID: 40661116
ISSN: 2352-5126
CID: 6071103
Keloid treatments: an evidence-based systematic review of recent advances
Walsh, Laura A; Wu, Ellen; Pontes, David; Kwan, Kevin R; Poondru, Sneha; Miller, Corinne H; Kundu, Roopal V
BACKGROUND:Keloids are pathologic scars that pose a significant functional and cosmetic burden. They are challenging to treat, despite the multitude of treatment modalities currently available. OBJECTIVE:The aim of this study was to conduct an evidence-based review of all prospective data regarding keloid treatments published between 2010 and 2020. METHODS:A systematic literature search of PubMed (National Library of Medicine), Embase (Elsevier), and Cochrane Library (Wiley) was performed in November of 2020. Search strategies with the keywords "keloid" and "treatment" were performed by a medical librarian. The search was limited to prospective studies that were peer-reviewed, reported on clinical outcomes of keloid therapies, and were published in the English language between January 1, 2010, and November 24, 2020. RESULTS:A total of 3462 unique citations were identified, of which 108 studies met inclusion criteria. Current literature supports silicone gel or sheeting with corticosteroid injections as first-line therapy for keloids. Adjuvant intralesional 5-fluorouracil (5-FU), bleomycin, or verapamil can be considered, although mixed results have been reported with each. Laser therapy can be used in combination with intralesional corticosteroids or topical steroids with occlusion to improve drug penetration. Excision of keloids with immediate post-excision radiation therapy is an effective option for recalcitrant lesions. Finally, silicone sheeting and pressure therapy have evidence for reducing keloid recurrence. CONCLUSIONS:This review was limited by heterogeneity of subject characteristics and study outcome measures, small sample sizes, and inconsistent study designs. Larger and more robust controlled studies are necessary to further understand the variety of existing and emerging keloid treatments, including corticosteroids, cryotherapy, intralesional injections, lasers, photodynamic therapy, excision and radiation, pressure dressings, and others.
PMCID:10012475
PMID: 36918908
ISSN: 2046-4053
CID: 6071102
Validation of a hand-mounted wearable sensor for scratching movements in adults with atopic dermatitis
Yang, Albert F; Chun, Keum San; Yu, Lian; Walter, Jessica R; Kim, Donghyun; Lee, Jong Yoon; Jeong, Hyoyoung; Keller, Matthew C; Seshadri, Dhruv R; Olagbenro, Matthew O; Bae, Jee Won; Reuther, William; Wu, Ellen; Okamoto, Kazuaki; Ikoma, Akihiko; Lio, Peter A; Fishbein, Anna B; Paller, Amy S; Xu, Shuai
PMID: 36156307
ISSN: 1097-6787
CID: 6071101
Nondestructive versus advanced post-transplant lymphoproliferative disorder in a single-center pediatric kidney transplant population
Wu, Ellen; Lee, Joo-Young; Gelarden, Ian; Engen, Rachel M
BACKGROUND:Pediatric kidney transplant recipients are at risk for the development of post-transplant lymphoproliferative disorders (PTLD), a group of potentially devastating diseases that present on a spectrum of severity ranging from nondestructive PTLD to more histologically destructive lesions. Currently, there is inadequate evidence to guide evaluation and management of nondestructive PTLD. METHODS:This is a single-center case series of pediatric kidney transplant recipients between January 1, 2008 and December 31, 2019, who were diagnosed with PTLD. The aim was to describe clinical characteristics, presentation, and management of nondestructive versus advanced PTLD. RESULTS:Eighteen patients were diagnosed with nondestructive PTLD and seven with more advanced PTLD histopathology. The majority (66.7%) of nondestructive PTLD patients (n = 16) presented with tonsillar hypertrophy and/or snoring and were managed conservatively, with minimal reduction in tacrolimus dose and no further evaluation. No patient progressed to more advanced PTLD. Advanced PTLD patients (n = 7) were more likely to present with fever, elevated creatinine, a new mass of gastrointestinal symptoms. They received workup with imaging and oncology consultation, and were managed with chemotherapy. CONCLUSIONS:Patients with nondestructive PTLD often present with symptoms of sleep-disordered breathing and can be managed conservatively with excellent clinical outcomes. More study is needed to guide care of this under-researched population.
PMID: 35098630
ISSN: 1399-3046
CID: 6071100
Use of technology for the objective evaluation of scratching behavior: A systematic review
Yang, Albert F; Nguyen, Morgan; Li, Alvin W; Lee, Brad; Chun, Keum San; Wu, Ellen; Fishbein, Anna B; Paller, Amy S; Xu, Shuai
INTRODUCTION/BACKGROUND:Pruritus is a common symptom across various dermatologic conditions, with a negative impact on quality of life. Devices to quantify itch objectively primarily use scratch as a proxy. This review compares and evaluates the performance of technologies aimed at objectively measuring scratch behavior. METHODS:Articles identified from literature searches performed in October 2020 were reviewed and those that did not report a primary statistical performance measure (eg, sensitivity, specificity) were excluded. The articles were independently reviewed by 2 authors. RESULTS:(ρ) = 0.18-0.40 for itch measured using a visual analog scale). This may be due to varied subjective perception of itch or actigraphy's underestimation of scratch. CONCLUSION/CONCLUSIONS:Actigraphy's large variability in performance and limited understanding of its specificity for scratch merits larger studies looking at validation of data analysis algorithms and device performance, particularly within target patient populations.
PMCID:8593746
PMID: 34816131
ISSN: 2666-3287
CID: 6071099